Electrical carotid sinus stimulation in treatment resistant arterial hypertension

Autonomic Neuroscience: Basic and Clinical

Volumn 172, Issue 1-2, 2012, Pages 31-36

  Jordan, Jens ^a   Heusser, Karsten ^a   Brinkmann, Julia ^a   Tank, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Arterial hypertension; Baroreflex; Sympathetic nervous system

Indexed keywords

ADRENERGIC SYSTEM; ANIMAL MODEL; BLOOD PRESSURE; CAROTID SINUS MASSAGE; CHRONIC KIDNEY FAILURE; DOG; ELECTRIC FIELD; ELECTROSTIMULATION; HEART; HEART FAILURE; HEART INFARCTION; HUMAN; IMPLANT; IMPLANTATION; KIDNEY; KIDNEY INJURY; NONHUMAN; PATHOPHYSIOLOGY; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; SENSORY NERVE; SYMPATHETIC TONE; VASCULARIZATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BAROREFLEX; CAROTID SINUS; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; SYMPATHETIC NERVOUS SYSTEM;

EID: 84870700186     PISSN: 15660702     EISSN: 18727484     Source Type: Journal    
DOI: 10.1016/j.autneu.2012.10.009     Document Type: Review

References (47)

1. Amann K., Rump L.C., Simonaviciene A., Oberhauser V., Wessels S., Orth S.R., Gross M.L., Koch A., Bielenberg G.W., Van Kats J.P., Ehmke H., Mall G., Ritz E. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J. Am. Soc. Nephrol. 2000, 11:1469-1478.
2. Annon. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
3. Bakris G.L., Nadim M.K., Haller H., Lovett E.G., Schafer J.E., Bisognano J.D. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J. Am. Soc. Hypertens. 2012, 6:152-158.
4. Bhan V., Yan R.T., Leiter L.A., Fitchett D.H., Langer A., Lonn E., Tan M., Silagy S., Goodman S.G., Yan A.T. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. Am. J. Cardiol. 2010, 106:1270-1276.
5. Bisognano J.D., Bakris G., Nadim M.K., Sanchez L., Kroon A.A., Schafer J., de Leeuw P.W., Sica D.A. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J. Am. Coll. Cardiol. 2011, 58:765-773.
6. Bisognano J.D., Kaufman C.L., Bach D.S., Lovett E.G., de L.P. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J. Am. Coll. Cardiol. 2011, 57:1787-1788.
7. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., White A., Cushman W.C., White W., Sica D., Ferdinand K., Giles T.D., Falkner B., Carey R.M. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
8. Cowley A.J., Liard J.F., Guyton A.C. Role of baroreceptor reflex in daily control of arterial blood pressure and other variables in dogs. Circ. Res. 1973, 32:564-576.
9. Cuspidi C., Macca G., Sampieri L., Michev I., Salerno M., Fusi V., Severgnini B., Meani S., Magrini F., Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J. Hypertens. 2001, 19:2063-2070.
10. Delius W., Hagbarth K.E., Hongell A., Wallin B.G. General characteristics of sympathetic activity in human muscle nerves. Acta Physiol. Scand. 1972, 84:65-81.
11. Dibona G.F. Neural control of renal function in health and disease. Clin. Auton. Res. 1994, 4:69-74.
12. Eckberg D.L., Wallin B.G., Fagius J., Lundberg L., Torebjork H.E. Prospective study of symptoms after human microneurography. Acta Physiol. Scand. 1989, 137:567-569.
13. Egan B.M., Zhao Y., Axon R.N., Brzezinski W.A., Ferdinand K.C. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011, 124:1046-1058.
14. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
15. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A., Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998, 31:68-72.
16. Hamar P., Kokeny G., Liptak P., Krtil J., Adamczak M., Amann K., Ritz E., Gross M.L. The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp. Nephrol. 2007, 105:e124-e136.
17. Hausberg M., Mark A.L., Winniford M.D., Brown R.E., Somers V.K. Sympathetic and vascular effects of short-term passive smoke exposure in healthy nonsmokers. Circulation 1997, 96:282-287.
18. Heusser K., Tank J., Luft F.C., Jordan J. Baroreflex failure. Hypertension 2005, 45:834-839.
19. Heusser K., Tank J., Engeli S., Diedrich A., Menne J., Eckert S., Peters T., Sweep F.C., Haller H., Pichlmaier A.M., Luft F.C., Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010, 55:619-626.
20. Hogarth A.J., Mackintosh A.F., Mary D.A. The sympathetic drive after acute myocardial infarction in hypertensive patients. Am. J. Hypertens. 2006, 19:1070-1076.
21. Hoppe U.C., Brandt M.C., Wachter R., Beige J., Rump L.C., Kroon A.A., Cates A.W., Lovett E.G., Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J. Am. Soc. Hypertens. 2012, 6:270-276.
22. Irzyniec T., Mall G., Greber D., Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am. J. Hypertens. 1992, 5:437-443.
23. Jordan J., Tank J., Diedrich A., Robertson D., Shannon J.R. Vasopressin and blood pressure in humans. Hypertension 2000, 36:E3-E4.
24. Ketch T., Biaggioni I., Robertson R., Robertson D. Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation 2002, 105:2518-2523.
25. Krieger E.M. Neurogenic hypertension in the rat. Circ. Res. 1964, 15:511-521.
26. Lloyd-Jones D.M., Evans J.C., Larson M.G., O'donnell C.J., Roccella E.J., Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594-599.
27. Lohmeier T.E., Irwin E.D., Rossing M.A., Serdar D.J., Kieval R.S. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension 2004, 43:306-311.
28. Lohmeier T.E., Dwyer T.M., Hildebrandt D.A., Irwin E.D., Rossing M.A., Serdar D.J., Kieval R.S. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension 2005, 46:1194-1200.
29. Lohmeier T.E., Dwyer T.M., Irwin E.D., Rossing M.A., Kieval R.S. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension 2007, 49:1307-1314.
30. Lohmeier T.E., Hildebrandt D.A., Dwyer T.M., Barrett A.M., Irwin E.D., Rossing M.A., Kieval R.S. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 2007, 49:373-379.
31. Mohaupt M.G., Schmidli J., Luft F.C. Management of uncontrollable hypertension with a carotid sinus stimulation device. Hypertension 2007, 50:825-828.
32. Neistadt A., Schwartz S.I. Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension. Surgery 1967, 61:923-931.
33. Parsonnet V., Rothfeld E.L., Raman K.V., Myers G.H. Electrical stimulation of the carotid sinus nerve. Surg. Clin. North Am. 1969, 49:589-596.
34. Peters T.K., Koralewski H.E., Zerbst E. The principle of electrical carotid sinus nerve stimulation: a nerve pacemaker system for angina pectoris and hypertension therapy. Ann. Biomed. Eng. 1980, 8:445-458.
35. Rothfeld E.L., Parsonnet V., Raman K.V., Zucker I.R., Tiu R. The effect of carotid sinus nerve stimulation on cardiovascular dynamics in man. Angiology 1969, 20:213-218.
36. Scheffers I.J., Kroon A.A., Schmidli J., Jordan J., Tordoir J.J., Mohaupt M.G., Luft F.C., Haller H., Menne J., Engeli S., Ceral J., Eckert S., Erglis A., Narkiewicz K., Philipp T., de Leeuw P.W. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J. Am. Coll. Cardiol. 2010, 56:1254-1258.
37. Schlaich M.P., Sobotka P.A., Krum H., Lambert E., Esler M.D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N. Engl. J. Med. 2009, 361:932-934.
38. Schmidli J., Savolainen H., Eckstein F., Irwin E., Peters T.K., Martin R., Kieval R., Cody R., Carrel T. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular 2007, 15:63-69.
39. Strojek K., Grzeszczak W., Gorska J., Leschinger M.I., Ritz E. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy?. J. Am. Soc. Nephrol. 2001, 12:602-605.
40. Thrasher T.N. Unloading arterial baroreceptors causes neurogenic hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282:R1044-R1053.
41. Tordoir J.H., Scheffers I., Schmidli J., Savolainen H., Liebeskind U., Hansky B., Herold U., Irwin E., Kroon A.A., de L.P., Peters T.K., Kieval R., Cody R. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur. J. Vasc. Endovasc. Surg. 2007, 33:414-421.
42. Van Vliet B.N., Chafe L.L., Montani J.P. Contribution of baroreceptors and chemoreceptors to ventricular hypertrophy produced by sino-aortic denervation in rats. J. Physiol. 1999, 516(Pt 3):885-895.
43. Wallin B.G., Sundlof G., Delius W. The effect of carotid sinus nerve stimulation on muscle and skin nerve sympathetic activity in man. Pflugers Arch. 1975, 358:101-110.
44. Weisz J., Emri M., Fent J., Lengyel Z., Marian T., Horvath G., Bogner P., Tron L., Adam G. Right prefrontal activation produced by arterial baroreceptor stimulation: a PET study. Neuroreport 2001, 12:3233-3238.
45. Wolf-Maier K., Cooper R.S., Kramer H., Banegas J.R., Giampaoli S., Joffres M.R., Poulter N., Primatesta P., Stegmayr B., Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004, 43:10-17.
46. Wustmann K., Kucera J.P., Scheffers I., Mohaupt M., Kroon A.A., de Leeuw P.W., Schmidli J., Allemann Y., Delacretaz E. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009, 54:530-536.
47. Zilch O., Vos P.F., Oey P.L., Cramer M.J., Ligtenberg G., Koomans H.A., Blankestijn P.J. Sympathetic hyperactivity in hemodialysis patients is reduced by short daily hemodialysis. J. Hypertens. 2007, 25:1285-1289.